Marshall Stanton Sells 1,259 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 1,259 shares of the company’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total transaction of $44,933.71. Following the sale, the senior vice president directly owned 41,921 shares in the company, valued at $1,496,160.49. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Artivion Stock Performance

NYSE:AORT opened at $38.14 on Friday. The stock has a market capitalization of $1.83 billion, a P/E ratio of 190.71 and a beta of 1.59. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $48.25. The firm has a 50 day moving average of $42.09 and a 200-day moving average of $43.05.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Citizens Jmp lifted their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.97.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. lifted its stake in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the period. XTX Topco Ltd acquired a new stake in shares of Artivion during the fourth quarter worth $746,000. Susquehanna Portfolio Strategies LLC increased its holdings in Artivion by 21.5% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock valued at $1,849,000 after purchasing an additional 7,186 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in Artivion in the fourth quarter valued at about $248,000. Finally, Millennium Management LLC boosted its holdings in Artivion by 1.0% during the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after buying an additional 893 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.